**Project title:**

Reducing the risk of stroke in AF: using the NICE PDA with patients not currently treated with anticoagulants

**Project aims:**

To reduce the risk of stroke in susceptible patients, by ensuring that AF is treated according to patient preference. To support greater patient involvement in selecting treatment options for AF, by promoting the use of the NICE PDA.

**Outcomes:**

The gross number of untreated patients in Solihull CCG at baseline was 1,759. To date, AF reviews have been conducted for 1,116 of these patients.

The outcome, in terms of reduced risk of stroke, is difficult to quantify, but admissions for cerebrovascular disease fell from the period April to December 2014, to the same period in 2015.  This fall could, at least in part, be a result of this project. There could be a financial benefit to CCG in the long term, the prospect of which helped to establish the support of finance for this project.

**Cost:**

The project incurred costs: the prescribing of DOACs has increased by £339,257 on the previous year, or +95%, which compares with +61.8% for England (figures from Keele University, Centre for Medicines Optimisation: Dec-15 data).